Anavex Stockholders Vote on the Whole Board Sept. 24. The Cure Period for Its Late 10-Q Could Run to Nov. 16 — If Nasdaq Accepts the Plan.

by Carter Whitfield · August 17, 2026

Equities Reporter, The SmallCap Signal

Anavex Life Sciences Corp. (Nasdaq: AVXL) has asked its stockholders to return a WHITE proxy card on Sept. 24 and elect all six directors its board has nominated. The vote is contested: PVG Asset Management Corporation and its principal, Patrick S. Adams, have put up a competing slate of six on a GOLD card. What sits underneath the contest is a sequence of dates that does not resolve in the company's favour before the meeting. Anavex told the SEC in May that if Nasdaq accepts its plan to cure a late quarterly report, the exchange may grant an exception running to Nov. 16 — roughly eight weeks after stockholders will have finished voting. That acceptance is Nasdaq's to give, and none of the filings and company announcements reviewed for this article records a decision on it.

The mechanics are straightforward enough. Anavex has set Sept. 24, 2026 as the date of its annual meeting and filed its definitive proxy statement on Aug. 11. Its slate, as named in the company's own Aug. 3 announcement, is Jiong Ma, who serves as independent chair, Peter Donhauser, Axel Paeger, Claus van der Velden, and two new nominees, Gautam Patel and Adrian Senderowicz. PVG's preliminary contested proxy statement, filed with the SEC on July 24, proposes Adams himself alongside Jason Kolbert, Ralf von Ziegesar, Rene Mora, John Boris and Curtis Hogue, each for a term ending at the next annual meeting. Because both slates are the full size of the board, the two cards are mutually exclusive in practice. PVG's preliminary filing leaves the meeting date and the record date as blanks; holders should take the record date for voting eligibility from the company's definitive proxy statement rather than from any secondary account, including this one.

The size of the challenger's position is on the record from both sides. PVG's own preliminary proxy statement says that "the PVG Parties collectively own an aggregate of 327,344 shares of Common Stock" — a share count stated as of the date of that filing. It is not a vote count and not, in that sentence, a percentage. The company translated the position into a percentage in its Aug. 3 release announcing a board refresh, in a sentence that is a conclusion the company draws rather than a bare statistic: PVG's statement, it said, "lacks any discussion of any plan or strategy for Anavex going forward, which leads us to conclude that PVG and Mr. Adams are seeking to gain effective control of the Company without paying you a premium for your investment, despite only owning 0.35% of the Company's outstanding shares of common stock as of July 30, 2026." The percentage is the company's own calculation, on its own share count, as of its own chosen date. A contest run from a stake that small is unusual but not unheard of; what makes this one worth reading closely is the state of the company's filing calendar going into it.

Anavex's fiscal year ends Sept. 30, which makes the quarter ended March 31, 2026 its fiscal second and the quarter ended June 30 its fiscal third. Neither report went in on schedule. The company filed a notification of late filing for the March quarter in May, and on Aug. 10 it filed another, this time for the June quarter. The explanation in Part III of that Aug. 10 notification — the filing's own narrative text, reproduced on StockTitan, not the site's summary of it — gives the reason directly: "The Company and its advisors require additional time to complete the preparation and review of the Form 10-Q, including in light of the Special Committee's review of certain matters related to the termination of Dr. Missling."

The late March-quarter report drew an exchange letter. In a Form 8-K filed May 22, 2026 under Item 3.01, Anavex disclosed that Nasdaq had notified it on May 20 that it was not in compliance with Listing Rule 5250(c)(1), the provision requiring timely periodic filings. The same 8-K sets out the clock: "As indicated in the Notice, the Company has until July 20, 2026, to submit a plan to regain compliance," and "[i]f Nasdaq accepts the Company's plan, it may grant an exception of up to 180 calendar days from the Form 10-Q's due date, or until November 16, 2026, for the Company to regain compliance." Two features of that language matter. The 180 days run from the report's own due date — not from the date of the notice, and not from the day a plan is submitted — so filing the plan does not itself extend anything. And the exception is conditional: the same 8-K states that "[i]f Nasdaq does not accept the Company's compliance plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel." The filing also says the notice "has no immediate effect on the listing of the Company's common stock, which continues to trade on The Nasdaq Global Select Market." Anavex announced on July 20 that it had submitted its compliance plan; coverage of that announcement described the plan as then under review by Nasdaq staff.

The Special Committee named in the Aug. 10 notification is the same body that removed the company's long-serving chief executive. According to Anavex's Form 8-K filed May 6, 2026 under Item 5.02, a special committee composed of independent directors of the board terminated Christopher Missling effective April 30, 2026, "for Cause (as defined in the Employment Agreement)" — a contractual classification made by that committee under his 2013 employment agreement, not a finding by a court or a regulator. The filing attributes the decision to conduct that the Special Committee believed was inconsistent with Company policy, and says the committee also requested that Missling resign as a member of the board. The filing does not describe that conduct further, and this article does not characterise it beyond the filing's own words. The company has since repeated the classification in its solicitation materials, telling stockholders on Aug. 3 that it is "working with urgency while ensuring the Company's operations continue without disruption following our termination 'for cause' of former CEO Christopher Missling and the resulting delay in filing Anavex's quarterly report with the SEC."

Four days later the board installed a former executive as caretaker. The same May 6 filing discloses that Terrie Kellmeyer was appointed interim chief executive on May 4, 2026, on an annual base salary of $500,000 with a target annual bonus of 30% of base salary, a $150,000 signing bonus and 200,000 stock options. Kellmeyer was the company's senior vice president of clinical development from November 2023 to May 2025 and has worked with Anavex as a senior advisor since; the same 8-K records that she has also been executive vice president, regulatory affairs at Aardvark Therapeutics since May 2025. The board has leaned on her development background in its solicitation materials, telling stockholders on Aug. 3 that she "spent her entire career in drug development building and leading clinical and regulatory functions across the full lifecycle of drug development."

Stockholders are not flying entirely blind on the numbers, and it would be wrong to suggest otherwise. On July 30 Anavex published preliminary fiscal second-quarter results covering the three months ended March 31, 2026: cash and cash equivalents of $127.4 million at March 31, 2026, against $102.6 million at the Sept. 30, 2025 fiscal year end; a net loss of $5.3 million, or $0.06 per share, versus $11.2 million and $0.13 in the year-ago quarter; research and development expense of $4.2 million against $9.9 million; and general and administrative expense of $2.3 million against $2.6 million. The release carries an explicit warning about the status of those figures: "The financial results in this press release are preliminary and subject to completion of the Company's financial closing procedures. Actual results may vary materially from these preliminary financial results due to the completion of the Company's financial closing procedures and other developments or information that may arise between now and the time of the finalization of the Company's financial results for three and six months ended March 31, 2026."

Set against the last quarter Anavex reported in the ordinary course, the direction of travel is visible — with the caveat that the two are not the same kind of number. In its Feb. 9, 2026 release covering the December quarter, the company reported final figures: $131.7 million of cash and cash equivalents at Dec. 31, 2025, a net loss of $5.7 million, or $0.06 per share, research and development expense of $4.7 million and general and administrative expense of $2.1 million. Research spending in the March quarter was reported, on a preliminary and unclosed basis, at $4.2 million — less than half the $9.9 million the company recorded for the year-ago March quarter, and below the $4.7 million final figure for the immediately preceding quarter. The runway language also moved, though the two statements are not stated on the same basis. In February the company said it "anticipates at its current cash utilization rate, an approximate cash runway of more than 3 years"; in July it said it "expects the cash balance at the end of the second fiscal quarter of 2026 to fund operations into mid-to-late fiscal 2028." One is a duration keyed to a spending rate, the other a period; Anavex's fiscal 2028 ends Sept. 30, 2028, which is inside three years of the February statement.

The company's affirmative case to holders is that it is already fixing itself. Its Aug. 3 release says that with the election of Patel, whom it describes as "an experienced investment executive with over 30 years of corporate finance, investment management and board leadership experience," and Senderowicz, "an accomplished pharmaceutical executive and physician-scientist with over 30 years of clinical and regulatory leadership experience across the life sciences industry," half the board will have been refreshed since February 2026 and all of its members will be independent. Axel Paeger joined the board inside that stretch: a separate 8-K filed Feb. 25, 2026 records his appointment effective Feb. 23 and the board's determination that he is an independent director. On the science, the company said on July 30 that it "remains firmly committed to our lead candidate oral blarcamesine (ANAVEX®2-73) for patients with Alzheimer's disease" and is "prioritizing engagement with the U.S. FDA to align on a clear, data-driven regulatory and clinical development strategy," concentrating on early Alzheimer's disease, Rett syndrome and Fragile X syndrome. In its solicitation materials the company has also argued that PVG's nominees lack the drug-development and regulatory expertise the board needs.

PVG's preliminary proxy statement runs the argument in the other direction, and readers should treat its contents as one side's characterisations rather than as established fact: it attacks the records of named incumbent directors, including the board chair's tenure at a special-purpose acquisition company and the audit chair's lack of biotechnology experience; it asserts that the interim chief executive's "brief tenure has already revealed an inability to steer complex clinical assets through critical checkpoints"; it faults the company's investor-relations arrangements; and it cites the late Form 10-Q and the resulting Nasdaq delinquency as evidence of what it calls the board's lack of administrative diligence. Anavex has not accepted any of those characterisations. The last item is the one element of the dissident case that is independently documented — by Anavex's own May 22 Item 3.01 filing — and even there the documentation establishes the delinquency, not the cause PVG assigns to it. PVG's July 24 statement is also preliminary; a definitive version governs what stockholders actually receive.

The documented risks sit in the filings rather than in the rhetoric. Anavex is a clinical-stage company with no approved product, so its cash balance and its spending rate carry the story. Its shares are inside a live exchange-compliance process under Rule 5250(c)(1), in which, per the company's own 8-K, an exception depends on Nasdaq accepting a plan and a refusal would send the company to a Nasdaq Hearings Panel. And the special-committee review that produced the for-cause termination of the chief executive is, on the company's own account in the Aug. 10 notification, part of why a periodic report is still outstanding. A note on prices: this article cites none. Monday's session was still under way at the time of writing, and the quote pages checked disagreed materially with one another on both the last trade and Friday's close, so no share-price figure met our sourcing standard. The dates, by contrast, are fixed — Sept. 24 for the vote, and Nov. 16 for the outside edge of a cure period that the vote will not wait for, and that the exchange has not yet granted.

Editor's note: as of the time of writing, no Form 10-Q for either the March or the June quarter appeared among the Anavex filings reviewed for this article. That is a statement about what this newsroom could see today, not a certification of the company's EDGAR record; readers should check EDGAR directly before relying on it.